Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus Lenvatinib in unresectable hepatocellular carcinoma
NCT05312216Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
durvalumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05312216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312216.